Last reviewed · How we verify
An Open-label, Randomized, 2-period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects
This is an open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study in healthy subjects.
Details
| Lead sponsor | Pfizer |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 14 |
| Start date | 2014-08 |
| Completion | 2014-10 |
Conditions
- Healthy
Interventions
- Oral Bosutinib
- Intravenous infusion of bosutinib
Primary outcomes
- Area under the Concentration-Time Curve (AUC) — 96 hours
AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Countries
United Kingdom